Study:
n/a
Rationale:
n/a
Purpose:
This is a Phase 1 study during which patients with low or intermediate-1 risk
myelodysplastic syndromes (MDS) will receive investigational study drug ARRY-614.
This study has 2 parts. In the first part, patients will receive increasing doses of study
drug in order to achieve the highest dose of the study drug possible that will not cause
unacceptable side effects. Approximately 50 patients from the US will be enrolled in Part 1
(Recruiting).
In the second part of the study, patients will receive the best dose of study drug
determined from the first part of the study and will be followed to see what side effects
and effectiveness the study drug has, if any, in treating the cancer. Approximately 30
patients from the US will be enrolled in Part 2 (Not yet recruiting; Expansion optional, as
per protocol).
Study Status: Recruiting
Recruiting:
Dr. M. Sekeres 866-233-8100
| Condition |
Intervention |
Phase |
|
Myelodysplastic Syndromes |
Drug: ARRY-614, p38/Tie2 inhibitor; oral |
Phase 1 |
Verified by
Array BioPharma
December, 2012
Sponsored by: Array BioPharma
Information provided by: Array BioPharma
ClinicalTrials.gov identifier: NCT01496495
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic
Cleveland, Ohio 44195
United States
n/a